On August 8, 20 16, Beijing Bio was established in Beijing, with the full name of Beijing Institute of Biological Products Co., Ltd. ... Its main products include vaccines, diagnostic preparations and other biological products. Its domestic immunization program products have the largest output and the most complete varieties in China. Beijing Bio is one of the four major vaccine companies in China.
Kexing Holding Biotechnology Co., Ltd. is a biopharmaceutical company headquartered in Beijing, which is listed on the global select market of Nasdaq, and is a China vaccine company listed in North America.
Domestic vaccine products have accelerated their rise.
At present, pneumonia vaccine products listed in China mainly include 7-valent pneumonia conjugate vaccine, 13-valent pneumonia conjugate vaccine and 23-valent pneumonia polysaccharide vaccine (7-valent pneumonia vaccine withdrew from the domestic market in 20 14).
Among them, the 23-valent pneumococcal polysaccharide vaccine adopts 23 widely prevalent and invasive serotypes of pneumococcus (including serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A,1a,/kloc-). 19A, 19F, 20, 22F, 23F, 33F) were cultured, inactivated and purified respectively, and then mixed and packaged.